Health equity can provide equal opportunity for patients to achieve the best care possible. Medtech leaders from Boston Scientific, Sequel Med Tech, and ZEISS Medical Technology share how healthcare delivery, data transparency, and industry collaboration can provide more value to patients.
AI and real-time data enhance care efficiency and access. And with healthcare workers in short supply, the rapid advancements in AI, IoMT, and related innovation offer patient access freedom, enhanced care delivery, and better outcomes.
The value-based care model, with a substantial monetary budget, necessitates on-time and correct risk stratification. As a result, new and incumbent care providers and payers are reinventing healthcare delivery, looking towards cutting-edge GenAI and machine learning technology to radically transform the healthcare delivery paradigm. This article explores how GenAI and machine learning-based risk stratification are revolutionizing a new era of personalized care, resulting in improved healthcare functions for payers and providers.
Light field technology is illuminating a path to a deeper understanding of patient anatomy, surgeon methodology, and surgical environments. Traditionally, spine surgery navigation has depended on surgeons combining pre-operative imaging with intra-operative anatomy to execute their treatment plans. However, with light field technology and depth sensors, these technologies digitize the entire operative field, merging it seamlessly with preoperative imaging, effectively bridging the gap between unseen and visible physical anatomy of the spine. This provides surgeons with a three-dimensional anatomical view that exceeds what the naked eye can discern.
North Carolina healthcare provider supplies clinicians with immediate, on-site access to 3D-printed anatomic models and support through Ricoh Managed Services.
Researchers have developed a new machine-learning model that can precisely make prognosis predictions for patients with osteosarcoma, based on the density of viable tumor cells post-treatment.
